250 related articles for article (PubMed ID: 23666316)
1. Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study.
Pavelka K; Szekanecz Z; Damjanov N; Majdan M; Nasonov E; Mazurov V; Fabo T; Bananis E; Jones H; Szumski A; Tang B; Kotak S; Koenig AS; Vasilescu R
Clin Rheumatol; 2013 Sep; 32(9):1275-81. PubMed ID: 23666316
[TBL] [Abstract][Full Text] [Related]
2. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS;
Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
[TBL] [Abstract][Full Text] [Related]
3. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
Wiland P; Dudler J; Veale D; Tahir H; Pedersen R; Bukowski J; Vlahos B; Williams T; Gaylord S; Kotak S
J Rheumatol; 2016 Jul; 43(7):1268-77. PubMed ID: 27252426
[TBL] [Abstract][Full Text] [Related]
5. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B
Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236
[TBL] [Abstract][Full Text] [Related]
6. High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register.
Iannone F; Gremese E; Gallo G; Sarzi-Puttini P; Botsios C; Trotta F; Gasperini S; Galeazzi M; Adami S; Cantini F; Sebastiani M; Gorla R; Marchesoni A; Giardina A; Foti R; Mele A; Bruschi E; Bagnato G; Erre GL; Lapadula G;
Clin Rheumatol; 2014 Jan; 33(1):31-7. PubMed ID: 23954923
[TBL] [Abstract][Full Text] [Related]
7. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis.
Bae SC; Gun SC; Mok CC; Khandker R; Nab HW; Koenig AS; Vlahos B; Pedersen R; Singh A
BMC Musculoskelet Disord; 2013 Jan; 14():13. PubMed ID: 23294908
[TBL] [Abstract][Full Text] [Related]
8. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
[TBL] [Abstract][Full Text] [Related]
9. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.
Schiff MH; Yu EB; Weinblatt ME; Moreland LW; Genovese MC; White B; Singh A; Chon Y; Woolley JM
Drugs Aging; 2006; 23(2):167-78. PubMed ID: 16536638
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).
Gibofsky A; Cannon GW; Harrison DJ; Joseph GJ; Bitman B; Chaudhari S; Collier DH
Clin Exp Rheumatol; 2015; 33(3):297-301. PubMed ID: 25738333
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.
van Riel PL; Freundlich B; MacPeek D; Pedersen R; Foehl JR; Singh A;
Ann Rheum Dis; 2008 Aug; 67(8):1104-10. PubMed ID: 17666447
[TBL] [Abstract][Full Text] [Related]
12. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
[TBL] [Abstract][Full Text] [Related]
13. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
[TBL] [Abstract][Full Text] [Related]
14. Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study.
Emery P; Kvien TK; Combe B; Freundlich B; Robertson D; Ferdousi T; Bananis E; Pedersen R; Koenig AS
Ann Rheum Dis; 2012 Jun; 71(6):989-92. PubMed ID: 22402142
[TBL] [Abstract][Full Text] [Related]
15. Predictors of response to etanercept-methotrexate treatment: a post hoc logistic regression analysis of a randomized, open-label study in Latin American patients with rheumatoid arthritis.
de la Vega M; Guerra Bautista G; Xavier RM; Pacheco-Tena C; Solano G; Pedersen RD; Szumski AE; Borlenghi C; Santana K; Vlahos B
Adv Rheumatol; 2021 Sep; 61(1):56. PubMed ID: 34496979
[TBL] [Abstract][Full Text] [Related]
16. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
[TBL] [Abstract][Full Text] [Related]
17. Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.
Keystone EC; Pope JE; Thorne JC; Poulin-Costello M; Phan-Chronis K; Vieira A; Haraoui B;
Rheumatology (Oxford); 2016 Feb; 55(2):327-34. PubMed ID: 26361879
[TBL] [Abstract][Full Text] [Related]
18. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis.
Pope JE; Haraoui B; Thorne JC; Vieira A; Poulin-Costello M; Keystone EC
Ann Rheum Dis; 2014 Dec; 73(12):2144-51. PubMed ID: 23979914
[TBL] [Abstract][Full Text] [Related]
19. Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone.
Wisłowska M; Jakubicz D
Rheumatol Int; 2007 May; 27(7):641-7. PubMed ID: 17235556
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial.
Kekow J; Moots RJ; Emery P; Durez P; Koenig A; Singh A; Pedersen R; Robertson D; Freundlich B; Sato R
Ann Rheum Dis; 2010 Jan; 69(1):222-5. PubMed ID: 19293160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
